Tokyo Tape
Sign in
← Medinet

Annual report

2370.TEDINET S100XB0H
Period2024-10-01 → 2025-09-30
Filed2025-12-17
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 83
MetricValuePeriodScopeSource row
Revenue¥810m2024-10-01 → 2025-09-30StandaloneNet sales
Revenue¥769m2023-10-01 → 2024-09-30StandaloneNet sales
Revenue¥662m2022-10-01 → 2023-09-30vStandaloneNet sales (5-year summary)
Revenue¥634m2021-10-01 → 2022-09-30vStandaloneNet sales (5-year summary)
Revenue¥683m2020-10-01 → 2021-09-30dStandaloneNet sales (5-year summary)
Operating income−¥1.4bn2024-10-01 → 2025-09-30StandaloneOperating income
Operating income−¥1.4bn2023-10-01 → 2024-09-30StandaloneOperating income
Ordinary income−¥1.3bn2024-10-01 → 2025-09-30StandaloneOrdinary income
Ordinary income−¥1.3bn2023-10-01 → 2024-09-30StandaloneOrdinary income
Ordinary income−¥1.4bn2022-10-01 → 2023-09-30vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.3bn2021-10-01 → 2022-09-30vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥871m2020-10-01 → 2021-09-30dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.4bn2024-10-01 → 2025-09-30StandaloneIncome before income taxes
Profit before tax−¥1.3bn2023-10-01 → 2024-09-30StandaloneIncome before income taxes
Net income−¥1.4bn2024-10-01 → 2025-09-30StandaloneProfit loss
Net income−¥1.3bn2023-10-01 → 2024-09-30StandaloneProfit loss
Net income−¥1.4bn2022-10-01 → 2023-09-30vStandaloneNet income loss (5-year summary)
Net income−¥1.3bn2021-10-01 → 2022-09-30vStandaloneNet income loss (5-year summary)
Net income−¥843m2020-10-01 → 2021-09-30dStandaloneNet income loss (5-year summary)
Total assets¥4.3bnat 2025-09-30StandaloneAssets
Total assets¥5.7bnat 2024-09-30StandaloneAssets
Total assets¥5.6bnat 2023-09-30vStandaloneTotal assets (5-year summary)
Total assets¥6.1bnat 2022-09-30vStandaloneTotal assets (5-year summary)
Total assets¥5.4bnat 2021-09-30dStandaloneTotal assets (5-year summary)
Total liabilities¥476mat 2025-09-30StandaloneLiabilities
Total liabilities¥509mat 2024-09-30StandaloneLiabilities
Net assets / equity¥3.8bnat 2025-09-30StandaloneNet assets
Net assets / equity¥5.2bnat 2024-09-30StandaloneNet assets
Net assets / equity¥5.0bnat 2023-09-30vStandaloneNet assets
Net assets / equity¥5.5bnat 2022-09-30vStandaloneNet assets (5-year summary)
Net assets / equity¥4.9bnat 2021-09-30dStandaloneNet assets (5-year summary)
Cash and deposits¥2.2bnat 2025-09-30StandaloneCash and deposits
Cash and deposits¥4.7bnat 2024-09-30StandaloneCash and deposits
Cash & equivalents¥2.7bnat 2025-09-30StandaloneCash and cash equivalents
Cash & equivalents¥4.7bnat 2024-09-30StandaloneCash and cash equivalents
Cash & equivalents¥4.4bnat 2023-09-30vStandaloneCash and cash equivalents
Cash & equivalents¥4.5bnat 2022-09-30vStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥4.1bnat 2021-09-30dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.4bn2024-10-01 → 2025-09-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.3bn2023-10-01 → 2024-09-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.3bn2022-10-01 → 2023-09-30vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.2bn2021-10-01 → 2022-09-30vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥975m2020-10-01 → 2021-09-30dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥565m2024-10-01 → 2025-09-30StandaloneNet cash provided by used in investment activities
Investing cash flow¥65m2023-10-01 → 2024-09-30StandaloneNet cash provided by used in investment activities
Investing cash flow¥3m2022-10-01 → 2023-09-30vStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥20m2021-10-01 → 2022-09-30vStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥344m2020-10-01 → 2021-09-30dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow−¥3m2024-10-01 → 2025-09-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.5bn2023-10-01 → 2024-09-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.2bn2022-10-01 → 2023-09-30vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.6bn2021-10-01 → 2022-09-30vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.1bn2020-10-01 → 2021-09-30dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-5.152024-10-01 → 2025-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-5.042023-10-01 → 2024-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.652022-10-01 → 2023-09-30vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.332021-10-01 → 2022-09-30vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-4.882020-10-01 → 2021-09-30dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥14.27at 2025-09-30StandaloneNet assets per share (5-year summary)
Net assets per share¥19.62at 2024-09-30StandaloneNet assets per share (5-year summary)
Net assets per share¥21.64at 2023-09-30vStandaloneNet assets per share (5-year summary)
Net assets per share¥26.03at 2022-09-30vStandaloneNet assets per share (5-year summary)
Net assets per share¥27.31at 2021-09-30dStandaloneNet assets per share (5-year summary)
Equity ratio88.8%at 2025-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio91.1%at 2024-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio89.2%at 2023-09-30vStandaloneEquity to asset ratio (5-year summary)
Equity ratio90.7%at 2022-09-30vStandaloneEquity to asset ratio (5-year summary)
Equity ratio90.8%at 2021-09-30dStandaloneEquity to asset ratio (5-year summary)
ROE-30.4%2024-10-01 → 2025-09-30StandaloneRate of return on equity (5-year summary)
ROE-25.0%2023-10-01 → 2024-09-30StandaloneRate of return on equity (5-year summary)
ROE-27.3%2022-10-01 → 2023-09-30vStandaloneRate of return on equity (5-year summary)
ROE-24.1%2021-10-01 → 2022-09-30vStandaloneRate of return on equity (5-year summary)
ROE-17.5%2020-10-01 → 2021-09-30dStandaloneRate of return on equity (5-year summary)
Shares issued264,729,198at 2025-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued264,515,306at 2024-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued232,160,757at 2023-09-30vStandaloneTotal number of issued shares (5-year summary)
Shares issued211,730,423at 2022-09-30vStandaloneTotal number of issued shares (5-year summary)
Shares issued178,750,423at 2021-09-30dStandaloneTotal number of issued shares (5-year summary)
Employees107at 2025-09-30StandaloneNumber of employees
Employees112at 2024-09-30StandaloneNumber of employees
Employees98at 2023-09-30vStandaloneNumber of employees
Employees96at 2022-09-30vStandaloneNumber of employees
Employees83at 2021-09-30dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2024-10-01 → 2025-09-30¥4m
Reconciling Itemsreconcilingdepreciation2024-10-01 → 2025-09-30¥15m
Reconciling Itemsreconcilingsegment assetsat 2025-09-30¥3.4bn
Reconciling Itemsreconcilingsegment profit2024-10-01 → 2025-09-30−¥563m
Cellular And Tissue Based Product Businessreportable segmentcapex2024-10-01 → 2025-09-30¥3m
Cellular And Tissue Based Product Businessreportable segmentdepreciation2024-10-01 → 2025-09-30¥22m
Cellular And Tissue Based Product Businessreportable segmentemployeesat 2025-09-3016 pure
Cellular And Tissue Based Product Businessreportable segmentrevenue2024-10-01 → 2025-09-30¥219,000
Cellular And Tissue Based Product Businessreportable segmentrevenue external2024-10-01 → 2025-09-30¥219,000
Cellular And Tissue Based Product Businessreportable segmentsegment assetsat 2025-09-30¥139m
Cellular And Tissue Based Product Businessreportable segmentsegment profit2024-10-01 → 2025-09-30−¥408m
Contracted Cell Manufacturing Businessreportable segmentcapex2024-10-01 → 2025-09-30¥20m
Contracted Cell Manufacturing Businessreportable segmentdepreciation2024-10-01 → 2025-09-30¥64m
Contracted Cell Manufacturing Businessreportable segmentemployeesat 2025-09-3078 pure
Contracted Cell Manufacturing Businessreportable segmentrevenue2024-10-01 → 2025-09-30¥810m
Contracted Cell Manufacturing Businessreportable segmentrevenue external2024-10-01 → 2025-09-30¥810m
Contracted Cell Manufacturing Businessreportable segmentsegment assetsat 2025-09-30¥687m
Contracted Cell Manufacturing Businessreportable segmentsegment profit2024-10-01 → 2025-09-30−¥475m
—segment totalcapex2024-10-01 → 2025-09-30¥24m
—segment totaldepreciation2024-10-01 → 2025-09-30¥86m
—segment totalrevenue2024-10-01 → 2025-09-30¥810m
—segment totalrevenue external2024-10-01 → 2025-09-30¥810m
—segment totalsegment assetsat 2025-09-30¥826m
—segment totalsegment profit2024-10-01 → 2025-09-30−¥883m
Reconciling Itemsreconcilingcapex2023-10-01 → 2024-09-30¥2m
Reconciling Itemsreconcilingdepreciation2023-10-01 → 2024-09-30¥18m
Reconciling Itemsreconcilingsegment assetsat 2024-09-30¥4.9bn
Reconciling Itemsreconcilingsegment profit2023-10-01 → 2024-09-30−¥577m
Cellular And Tissue Based Product Businessreportable segmentcapex2023-10-01 → 2024-09-30¥21m
Cellular And Tissue Based Product Businessreportable segmentdepreciation2023-10-01 → 2024-09-30¥36m
Cellular And Tissue Based Product Businessreportable segmentrevenue2023-10-01 → 2024-09-30¥245,000
Cellular And Tissue Based Product Businessreportable segmentrevenue external2023-10-01 → 2024-09-30¥245,000
Cellular And Tissue Based Product Businessreportable segmentsegment assetsat 2024-09-30¥116m
Cellular And Tissue Based Product Businessreportable segmentsegment profit2023-10-01 → 2024-09-30−¥435m
Contracted Cell Manufacturing Businessreportable segmentcapex2023-10-01 → 2024-09-30¥23m
Contracted Cell Manufacturing Businessreportable segmentdepreciation2023-10-01 → 2024-09-30¥61m
Contracted Cell Manufacturing Businessreportable segmentrevenue2023-10-01 → 2024-09-30¥768m
Contracted Cell Manufacturing Businessreportable segmentrevenue external2023-10-01 → 2024-09-30¥768m
Contracted Cell Manufacturing Businessreportable segmentsegment assetsat 2024-09-30¥667m
Contracted Cell Manufacturing Businessreportable segmentsegment profit2023-10-01 → 2024-09-30−¥374m
—segment totalcapex2023-10-01 → 2024-09-30¥44m
—segment totaldepreciation2023-10-01 → 2024-09-30¥97m
—segment totalrevenue2023-10-01 → 2024-09-30¥769m
—segment totalrevenue external2023-10-01 → 2024-09-30¥769m
—segment totalsegment assetsat 2024-09-30¥783m
—segment totalsegment profit2023-10-01 → 2024-09-30−¥808m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 961
ItemContextValueUnit
Property plant and equipmentCurrentYearInstant_NonConsolidatedMember356621000JPY
Patent rightPrior1YearInstant_NonConsolidatedMember14791000JPY
Patent rightCurrentYearInstant_NonConsolidatedMember12291000JPY
SoftwarePrior1YearInstant_NonConsolidatedMember45661000JPY
SoftwareCurrentYearInstant_NonConsolidatedMember38434000JPY
Software in progressPrior1YearInstant_NonConsolidatedMember40308000JPY
Software in progressCurrentYearInstant_NonConsolidatedMember17261000JPY
Intangible assetsPrior1YearInstant_NonConsolidatedMember100761000JPY
Intangible assetsCurrentYearInstant_NonConsolidatedMember67987000JPY
Investment securitiesPrior1YearInstant_NonConsolidatedMember101522000JPY
Investment securitiesCurrentYearInstant_NonConsolidatedMember154550000JPY
Long term loans receivablePrior1YearInstant_NonConsolidatedMember495250000JPY
Long term loans receivableCurrentYearInstant_NonConsolidatedMember459250000JPY
Claims provable in bankruptcy claims provable in rehabilitation and otherPrior1YearInstant_NonConsolidatedMember24478000JPY
Claims provable in bankruptcy claims provable in rehabilitation and otherCurrentYearInstant_NonConsolidatedMember23468000JPY
Long term prepaid expensesPrior1YearInstant_NonConsolidatedMember－JPY
Long term prepaid expensesCurrentYearInstant_NonConsolidatedMember1285000JPY
Guarantee deposits ioaPrior1YearInstant_NonConsolidatedMember61987000JPY
Guarantee deposits ioaCurrentYearInstant_NonConsolidatedMember62007000JPY
Allowance for doubtful accounts ioa by groupPrior1YearInstant_NonConsolidatedMember-519728000JPY
Allowance for doubtful accounts ioa by groupCurrentYearInstant_NonConsolidatedMember-482718000JPY
Investments and other assetsPrior1YearInstant_NonConsolidatedMember163509000JPY
Investments and other assetsCurrentYearInstant_NonConsolidatedMember217843000JPY
Noncurrent assetsPrior1YearInstant_NonConsolidatedMember686955000JPY
Noncurrent assetsCurrentYearInstant_NonConsolidatedMember642452000JPY
AssetsPrior1YearInstant_NonConsolidatedMember5700031000JPY
AssetsCurrentYearInstant_NonConsolidatedMember4254070000JPY
Accounts payable tradePrior1YearInstant_NonConsolidatedMember57502000JPY
Accounts payable tradeCurrentYearInstant_NonConsolidatedMember41074000JPY
Lease obligations clPrior1YearInstant_NonConsolidatedMember781000JPY
Lease obligations clCurrentYearInstant_NonConsolidatedMember－JPY
Accounts payable otherPrior1YearInstant_NonConsolidatedMember97284000JPY
Accounts payable otherCurrentYearInstant_NonConsolidatedMember77452000JPY
Accrued expensesPrior1YearInstant_NonConsolidatedMember9882000JPY
Accrued expensesCurrentYearInstant_NonConsolidatedMember9304000JPY
Income taxes payablePrior1YearInstant_NonConsolidatedMember28654000JPY
Income taxes payableCurrentYearInstant_NonConsolidatedMember10507000JPY
Deposits receivedPrior1YearInstant_NonConsolidatedMember7212000JPY
Deposits receivedCurrentYearInstant_NonConsolidatedMember6969000JPY
Provision for bonusesPrior1YearInstant_NonConsolidatedMember67604000JPY
Provision for bonusesCurrentYearInstant_NonConsolidatedMember72176000JPY
Other clPrior1YearInstant_NonConsolidatedMember－JPY
Other clCurrentYearInstant_NonConsolidatedMember15625000JPY
Current liabilitiesPrior1YearInstant_NonConsolidatedMember268922000JPY
Current liabilitiesCurrentYearInstant_NonConsolidatedMember233110000JPY
Deferred tax liabilitiesPrior1YearInstant_NonConsolidatedMember36319000JPY
Deferred tax liabilitiesCurrentYearInstant_NonConsolidatedMember15458000JPY
Asset retirement obligations nclPrior1YearInstant_NonConsolidatedMember160157000JPY
Asset retirement obligations nclCurrentYearInstant_NonConsolidatedMember162195000JPY
Provision for share based payments nclPrior1YearInstant_NonConsolidatedMember43865000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2024-09-30pass rounding
balance sheet identitynon_consolidated 2025-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-09-30pass
statement vs summary · net assetsnon_consolidated 2024-09-30pass
statement vs summary · net assetsnon_consolidated 2025-09-30pass
statement vs summary · operating cash flownon_consolidated 2023-10-01/2024-09-30pass
statement vs summary · operating cash flownon_consolidated 2024-10-01/2025-09-30pass
statement vs summary · revenuenon_consolidated 2023-10-01/2024-09-30pass
statement vs summary · revenuenon_consolidated 2024-10-01/2025-09-30pass
statement vs summary · total assetsnon_consolidated 2024-09-30pass
statement vs summary · total assetsnon_consolidated 2025-09-30pass